Q2 2024 Biomx Inc Earnings Call Transcript
Key Points
- BiomX Inc (PHGE) successfully merged with Adaptive Phage Therapeutics and completed a $50 million financing, strengthening its financial position.
- The company reported positive safety and efficacy results from the Phase 1b/2a trial of BX004, showing potential in treating chronic lung infections in cystic fibrosis patients.
- BiomX Inc (PHGE) has a diverse pipeline with both fixed phage cocktails and personalized phage treatments, addressing a broad range of bacterial strains and resistant mechanisms.
- The company expects to have sufficient funding to reach multiple important clinical milestones through the fourth quarter of 2025.
- Net income for the second quarter of 2024 was $4.5 million, a significant improvement from a net loss of $6.4 million in the same period of 2023.
- Research and development expenses increased significantly to $6.9 million in Q2 2024 from $3.8 million in Q2 2023, primarily due to clinical trial preparations.
- The company announced a reverse stock split, which may indicate concerns about maintaining stock price levels.
- Enrollment for the BX211 study has been challenging, spanning over more than two years, which could delay results.
- General and administrative expenses rose to $2.8 million in Q2 2024 from $2.3 million in Q2 2023, reflecting increased costs post-merger.
- Net cash used in operating activities increased to $22.6 million for the first half of 2024, up from $9.1 million in the same period of 2023, indicating higher operational costs.
Greetings, and welcome to BiomX second quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Ms. Marina Wolfson, Chief Financial Officer. Thank you, Ms. Wolfson. You may begin.
Thank you, and welcome to the BiomX conference call to review the second quarter 2024 financial results and provide an update on our business and programs.
Yesterday, we filed the quarterly report on Form 10-Q with the Securities and Exchange Commission. In addition, the press release became available at 06:30 AM Eastern Time today and can be found on our website at biomx.com. A replay of this call will also be available on the Investors section of our website.
As we begin, I'd like to review the safe harbor provision. All statements on this call that are not factual historic statements may be deemed forward-looking statements. For instance, we are using forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
